bpc-157 regulation fda regulatory status not approved peptide Exciting news for peptides coming out of today's fda warning bpc-157 peptide BPC

JAMA 327 , 138150 (2022)

Fresh Vegetables: Load up on color

These include: Nausea, vomiting, and diarrhoea (very common, especially during dose escalation) Reduced appetite and abdominal discomfort Constipation Risk of hypoglycaemia when used with insulin or sulphonylureas Pancreatitis and gallbladder disease have been reported Thyroid C-cell tumours have been observed in animal studies, though the relevance to humans is unknown Important safety considerations when using both treatments include: Mounjaro can reduce the effectiveness of oral contraceptives due to delayed gastric emptying

Chronic conditions typically require 4-8 weeks minimum before significant changes become apparent